DOCSLIB.ORG

Novel Functions for Angiotensin-Converting Enzymes

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Novel Functions for Angiotensin-Converting Enzymes View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector Current Biology, Vol. 12, R745–R752, October 29, 2002, ©2002 Elsevier Science Ltd. All rights reserved. PII S0960-9822(02)01255-1 Just The Beginning: Novel Functions Review for Angiotensin-Converting Enzymes 1 1 Urs Eriksson , Ursula Danilczyk and Josef M. results in the generation of the main effector molecule 2 Penninger angiotensin II, which acts both as a systemic and a locally generated paracrine or autocrine effector peptide [1–3] (Figure 1). The protease renin, which is Cardiovascular disease is predicted to be the secreted by juxtaglomerular cells at the renal afferent commonest cause of death worldwide by the year arterioles, cleaves the liver-derived precursor peptide 2020. Diabetes, smoking and hypertension are the angiotensinogen into the decameric peptide angio- main risk factors. The renin-angiotensin system plays tensin I. Angiotensin I is further hydrolyzed into the a key role in regulating blood pressure and fluid and vasoconstrictor octapeptide angiotensin II by the pro- electrolyte homeostasis in mammals. The discovery teolytic dipeptidase ACE, located on the luminal side of specific drugs that block either the key enzyme of of the vascular endothelium, and other non-ACE the renin-angiotensin system, angiotensin-convert- systems, such as tissue chymase at the tissue level [8]. ing enzyme (ACE), or the receptor for its main effec- ACE also inactivates the vasodilator peptides tor angiotensin II, was a major step forward in the bradykinin and kallidin. Thus, activation of the renin- treatment of hypertension and heart failure. In recent angiotensin system mainly results in a systemic vaso- years, however, the renin-angiotensin system has pressor response by blocking the hypotensive been shown to be a far more complex system than kinin-bradykinin pathway and by generation of the initially thought. It has become clear that additional vasoconstrictor angiotensin II [4]. peptide mediators are involved. Furthermore, a new Angiotensin II is not just a potent vasopressor which ACE, angiotensin-converting enzyme 2 (ACE2), has raises systemic blood pressure; it also mediates a been discovered which appears to negatively regu- broad array of physiological and pathophysiological late the renin-angiotensin system. In the heart, ACE2 effects by binding to specific cell membrane receptors deficiency results in severe impairment of cardiac [9,10]. So far, two distinct types of G-protein-coupled contractility and upregulation of hypoxia-induced receptors for angiotensin II have been cloned and char- genes. We shall discuss the interplay of the various acterised in humans and rodents. The angiotensin II effector peptides generated by angiotensin-convert- type 1 (AT1) and type 2 (AT2) receptors are heteroge- ing enzymes ACE and ACE2, highlighting the role of neously distributed in peripheral tissues and the brain ACE2 as a negative regulator of the renin-angiotensin [9,10]. The AT1 receptor is predominantly expressed in system. the kidneys, adrenal glands, vascular smooth muscle cells and the heart, and it is to this receptor that the regulatory actions of angiotensin II on blood pressure and salt/water balance have been attributed [9,11,12]. Introduction The AT2 receptor is present at high density during fetal The renin-angiotensin system is a complex regulatory development; in the adult, significant AT2 receptor system that plays a key role in maintaining blood expression occurs only in the adrenal medulla, uterus, pressure homeostasis, as well as fluid and salt ovary, vascular endothelium, adrenal glands and certain balance in mammals [1–4]. The angiotensin convert- areas in the brain [4,9]. The AT2 receptor is thought to ing-enzyme (ACE) is an important regulator of the counterbalance effects mediated by the AT1 receptor: it renin-angiotensin system. Recently, a homologue of appears to induce vasodilation and may be involved in human ACE, angiotensin-converting enzyme 2 (ACE2), the control of cell proliferation, differentiation and has been discovered [5,6]. Characterisation of its angiogenesis [4,10,11]. function and substrate specificity [5,6], together with data from ace2 mutant mice [7], suggests that ACE2 A Broad Array of Biologically Active Peptides negatively regulates the activated renin-angiotensin In vivo, angiotensin II is degraded into several meta- system. In this review we shall discuss the functions bolites by different enzymes (Figure 2). So far, it has of ACE and ACE2 and their substrates and products in been shown that at least five of these products are the regulation of the renin-angiotensin system. biologically active [4]. Interestingly, these metabolites have different biological effects. Angiotensin III, which Classical Model of the Renin-Angiotensin System is cleaved from angiotensin II by an aminopeptidase, In the classical pathway of the renin-angiotensin binds to both AT1 and AT2 receptors and acts similar system, activation of a cascade of enzymatic reactions to angiotensin II [13]. In contrast, angiotensin(1–7), a product of angiotensin II as well as of the angiotensin 1 IMBA, Institute for Molecular Biotechnology of the Austrian I metabolite angiotensin(1–9), appears to have vasodi- Academy of Sciences, C/o Dr. Bohr Gasse 7, A-1030 Vienna, latatory [14–16] and antiproliferative effects mediated 2 Austria. University Health Network, Departments of Medical by binding a novel, not yet defined, angiotensin(1–7) Biophysics and Immunology, University of Toronto, Toronto, receptor [17]. Ontario, Canada. 620 University Avenue, Toronto, Ontario, Angiotensin IV is generated from angiotensin III by an Canada M5G 2C1. E-mail: [email protected] as yet unknown pathway. In the kidneys, angiotensin IV Review R746 Figure 1. The renin-angiotensin system: Kininogen Angiotensinogen the classical picture. Renin Vasodilation B1 Kinin Angiotensin I ACE Non-ACE enzymes Inactive product Angiotensin II AT 1 receptor AT 2 recpetor Vasoconstriction Vasodilation Proliferation Apoptosis Hypertrophy Growth arrest Current Biology enhances natriuresis and increases renal blood flow. of ACE remains unclear, but the fact that fertility is There is evidence that, in the central nervous system, impaired in ace-deficient mice [22,23], but not in AT1A angiotensin IV facilitates memory retention and retrieval receptor knock-out mice [24], suggests that testicular [4,12]. The effects of angiotensin IV involve a novel AT4 ACE does not mediate its effects via angiotensin receptor [18,19]. The AT4 receptor has also been iden- II–AT1A interactions. Both ACE isoforms are mem- tified as an insulin-regulated aminopeptidase [19], sug- brane-bound protein and, at the cell surface, they gesting an indirect mechanism whereby angiotensin IV function as ectoenzymes which hydrolyze circulating might extend the half-life of biologically active neu- peptides. ACE may be cleaved from the cell surface ropeptides by competitive inhibition of AT4’s enzyme and act as a soluble enzyme, but the biological signif- activity [4,19]. icance of soluble ACE remains unclear. The diversity of the renin-angiotensin system is not ACE is currently thought to have two major activities: only demonstrated by the different effects of the it acts as a peptidyl dipeptidase which removes the various degradation products of angiotensin I and carboxy-terminal dipeptide from its substrate, and as angiotensin II. Characterisation of receptor specificities endopeptidase on substrates that are amidated at the and enzymes involved in the degradation of angiotensin carboxyl terminus (Figure 3). The emerging picture of metabolites has revealed far more complex mediator ACE function is that it is more than just a key enzyme systems than previously recognised. It appears that the that catalyses cleavage of angiotensin I to the potent complexity of the renin-angiotensin system guarantees vasoconstrictor peptide angiotensin II [3,4,20]. ACE also well-tuned adaptation of the blood supply of the body hydrolyzes the inactive angiotensin(1-9) peptide into the compartments and organs to all possible physiologic vasodilator metabolite angiotensin(1–7) [25], and it is conditions. In this complex system, a key role has been additionally thought to inactivate the vasodilator pep- attributed to the rate-limiting enzymes, ACE and ACE2, tides bradykinin and kallidin [25,26]. Furthermore, it acts via their action in generating or degrading the various as endopeptidase on the multi-functional neuropep- active mediators. tides substance P and cholecystokinin, and may degrade the luteinizing hormone releasing hormone Angiotensin Converting-Enzyme (ACE) [4,27]. In this context, however, its biological signifi- ACE was termed a ‘hypertensin-converting enzyme’ cance is not known, nor has the possibility of functional when it was initially isolated in 1956 [20]. The human crosstalk between the systems been excluded. ace gene, located on chromosome 17, encodes a The finding that ACE catalyzes cleavage of angio- 180 kDa protein with two homologous domains. Each tensin I into angiotensin II, together with the eluci- domain has an active zinc-binding motif, His-Glu-X-X- dation of ACE’s three-dimensional structure, led to the His, which is found in many peptidases [3,21] (Figure design of specific ACE inhibitors. Inhibition of ACE 3). ACE is anchored to the plasma membrane through results in lowering of blood pressure by impaired for- a single carboxy-terminal transmembrane
Load more

Recommended publications
  • Synthetic Nanobodies As Angiotensin Receptor Blockers
    Synthetic nanobodies as angiotensin receptor blockers Conor McMahona,1, Dean P. Stausb,c,1, Laura M. Winglerb,c,1,2, Jialu Wangc, Meredith A. Skibaa, Matthias Elgetid,e, Wayne L. Hubbelld,e, Howard A. Rockmanc,f, Andrew C. Krusea,3, and Robert J. Lefkowitzb,c,g,3 aDepartment of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115; bHoward Hughes Medical Institute, Duke University Medical Center, Durham, NC 27710; cDepartment of Medicine, Duke University Medical Center, Durham, NC 27710; dJules Stein Eye Institute, University of California, Los Angeles, CA 90095; eDepartment of Chemistry and Biochemistry, University of California, Los Angeles, CA 90095; fDepartment of Cell Biology, Duke University Medical Center, Durham, NC 27710; and gDepartment of Biochemistry, Duke University Medical Center, Durham, NC 27710 Edited by K. Christopher Garcia, Stanford University, Stanford, CA, and approved July 13, 2020 (received for review May 6, 2020) There is considerable interest in developing antibodies as functional a need for more broadly applicable methodologies to discover modulators of G protein-coupled receptor (GPCR) signaling for both antibody fragments explicitly directed to the membrane- therapeutic and research applications. However, there are few an- embedded domains with limited surface exposure. tibody ligands targeting GPCRs outside of the chemokine receptor The angiotensin II type 1 receptor (AT1R) is a GPCR that group. GPCRs are challenging targets for conventional antibody dis- exemplifies the opportunities and the challenges surrounding an- covery methods, as many are highly conserved across species, are tibody drug development. Both the endogenous peptide agonist of biochemically unstable upon purification, and possess deeply buried the AT1R (angiotensin II) and small-molecule inhibitors (angio- ligand-binding sites.
    [Show full text]
  • Properties of Chemically Oxidized Kininogens*
    Vol. 50 No. 3/2003 753–763 QUARTERLY Properties of chemically oxidized kininogens*. Magdalena Nizio³ek, Marcin Kot, Krzysztof Pyka, Pawe³ Mak and Andrzej Kozik½ Faculty of Biotechnology, Jagiellonian University, Kraków, Poland Received: 30 May, 2003; revised: 01 August, 2003; accepted: 11 August, 2003 Key words: bradykinin, N-chlorosuccinimide, chloramine-T, kallidin, kallikrein, reactive oxygen species Kininogens are multifunctional proteins involved in a variety of regulatory pro- cesses including the kinin-formation cascade, blood coagulation, fibrynolysis, inhibi- tion of cysteine proteinases etc. A working hypothesis of this work was that the prop- erties of kininogens may be altered by oxidation of their methionine residues by reac- tive oxygen species that are released at the inflammatory foci during phagocytosis of pathogen particles by recruited neutrophil cells. Two methionine-specific oxidizing reagents, N-chlorosuccinimide (NCS) and chloramine-T (CT), were used to oxidize the high molecular mass (HK) and low molecular mass (LK) forms of human kininogen. A nearly complete conversion of methionine residues to methionine sulfoxide residues in the modified proteins was determined by amino acid analysis. Production of kinins from oxidized kininogens by plasma and tissue kallikreins was significantly lower (by at least 70%) than that from native kininogens. This quenching effect on kinin release could primarily be assigned to the modification of the critical Met-361 residue adja- cent to the internal kinin sequence in kininogen. However, virtually no kinin could be formed by human plasma kallikrein from NCS-modified HK. This observation sug- gests involvement of other structural effects detrimental for kinin production. In- deed, NCS-oxidized HK was unable to bind (pre)kallikrein, probably due to the modifi- cation of methionine and/or tryptophan residues at the region on the kininogen mole- cule responsible for the (pro)enzyme binding.
    [Show full text]
  • Acute Restraint Stress Induces Cholecystokinin Release Via Enteric
    Neuropeptides 73 (2019) 71–77 Contents lists available at ScienceDirect Neuropeptides journal homepage: www.elsevier.com/locate/npep Acute restraint stress induces cholecystokinin release via enteric apelin T ⁎ Mehmet Bülbüla, , Osman Sinena, Onur Bayramoğlua, Gökhan Akkoyunlub a Department of Physiology, Akdeniz University, Faculty of Medicine, Antalya, Turkey b Department of Histology and Embryology, Akdeniz University, Faculty of Medicine, Antalya, Turkey ARTICLE INFO ABSTRACT Keywords: Stress increases the apelin content in gut, while exogenous peripheral apelin has been shown to induce chole- Apelin cystokinin (CCK) release. The present study was designed to elucidate (i) the effect of acute stress on enteric Restraint stress production of apelin and CCK, (ii) the role of APJ receptors in apelin-induced CCK release depending on the Cholecystokinin nutritional status. CCK levels were assayed in portal vein blood samples obtained from stressed (ARS) and non- APJ receptor stressed (NS) rats previously injected with APJ receptor antagonist F13A or vehicle. Duodenal expressions of Fasting apelin, CCK and APJ receptor were detected by immunohistochemistry. ARS increased the CCK release which was abolished by selective APJ receptor antagonist F13A. The stimulatory effect of ARS on CCK production was only observed in rats fed ad-libitum. Apelin and CCK expressions were upregulated by ARS. In addition to the duodenal I cells, APJ receptor was also detected in CCK-producing myenteric neurons. Enteric apelin appears to regulate the stress-induced changes in GI functions through CCK. Therefore, apelin/APJ receptor systems seem to be a therapeutic target for the treatment of stress-related gastrointestinal disorders. 1. Introduction for APJ in rodents (De Mota et al., 2000; Medhurst et al., 2003).
    [Show full text]
  • Sized Neuropeptides
    M ETHODS IN MOLECULAR BIOLOGY™ Series Editor John M. Walker School of Life Sciences University of Hertfordshire Hatfield, Hertfordshire, AL10 9AB, UK For further volumes: http://www.springer.com/series/7651 Neuropeptides Methods and Protocols Edited by Adalberto Merighi Dipartimento di Morfofisiologia Veterinaria, Università degli Studi di Torino, Grugliasco, TO, Italy; Istituto Nazionale di Neuroscienze (INN), Università degli Studi di Torino, Grugliasco, TO, Italy Editor Adalberto Merighi Dipartimento di Morfofisiologia Veterinaria Università degli Studi di Torino and Istituto Nazionale di Neuroscienze (INN) Università degli Studi di Torino Grugliasco, TO, Italy [email protected] Please note that additional material for this book can be downloaded from http://extras.springer.com ISSN 1064-3745 e-ISSN 1940-6029 ISBN 978-1-61779-309-7 e-ISBN 978-1-61779-310-3 DOI 10.1007/978-1-61779-310-3 Springer New York Dordrecht Heidelberg London Library of Congress Control Number: 2011936011 © Springer Science+Business Media, LLC 2011 All rights reserved. This work may not be translated or copied in whole or in part without the written permission of the publisher (Humana Press, c/o Springer Science+Business Media, LLC, 233 Spring Street, New York, NY 10013, USA), except for brief excerpts in connection with reviews or scholarly analysis. Use in connection with any form of information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed is forbidden. The use in this publication of trade names, trademarks, service marks, and similar terms, even if they are not identified as such, is not to be taken as an expression of opinion as to whether or not they are subject to proprietary rights.
    [Show full text]
  • A Metabolically Stable Apelin-17 Analog Decreases AVP-Induced Antidiuresis and Improves Hyponatremia
    ARTICLE https://doi.org/10.1038/s41467-020-20560-y OPEN A metabolically stable apelin-17 analog decreases AVP-induced antidiuresis and improves hyponatremia Adrien Flahault 1,3, Pierre-Emmanuel Girault-Sotias 1,3, Mathilde Keck1, Rodrigo Alvear-Perez1, ✉ Nadia De Mota1, Lucie Estéoulle2, Sridévi M. Ramanoudjame2, Xavier Iturrioz1, Dominique Bonnet 2 & ✉ Catherine Llorens-Cortes 1 1234567890():,; Apelin and arginine-vasopressin (AVP) are conversely regulated by osmotic stimuli. We therefore hypothesized that activating the apelin receptor (apelin-R) with LIT01-196, a metabolically stable apelin-17 analog, may be beneficial for treating the Syndrome of Inap- propriate Antidiuresis, in which AVP hypersecretion leads to hyponatremia. We show that LIT01-196, which behaves as a potent full agonist for the apelin-R, has an in vivo half-life of 156 minutes in the bloodstream after subcutaneous administration in control rats. In col- lecting ducts, LIT01-196 decreases dDAVP-induced cAMP production and apical cell surface expression of phosphorylated aquaporin 2 via AVP type 2 receptors, leading to an increase in aqueous diuresis. In a rat experimental model of AVP-induced hyponatremia, LIT01-196 subcutaneously administered blocks the antidiuretic effect of AVP and the AVP-induced increase in urinary osmolality and induces a progressive improvement of hyponatremia. Our data suggest that apelin-R activation constitutes an original approach for hyponatremia treatment. 1 Laboratory of Central Neuropeptides in the Regulation of Body Fluid Homeostasis and Cardiovascular Functions, Center for Interdisciplinary Research in Biology, INSERM, Unit U1050, Centre National de la Recherche Scientifique, Unite Mixte de Recherche 7241, Collège de France, Paris, France. 2 Laboratory of Therapeutic Innovation, Unité Mixte de Recherche 7200, Centre National de la Recherche Scientifique, Faculty of Pharmacy, University of Strasbourg, Illkirch, France.
    [Show full text]
  • Obesity, Bioactive Lipids, and Adipose Tissue Inflammation in Insulin
    nutrients Review Obesity, Bioactive Lipids, and Adipose Tissue Inflammation in Insulin Resistance Iwona Kojta, Marta Chaci ´nskaand Agnieszka Błachnio-Zabielska * Department of Hygiene, Epidemiology and Metabolic Disorders, Medical University of Bialystok, Jana Kili´nskiego1, 15-089 Bialystok, Poland; [email protected] (I.K.); [email protected] (M.C.) * Correspondence: [email protected] Received: 1 April 2020; Accepted: 30 April 2020; Published: 3 May 2020 Abstract: Obesity is a major risk factor for the development of insulin resistance and type 2 diabetes. The exact mechanism by which adipose tissue induces insulin resistance is still unclear. It has been demonstrated that obesity is associated with the adipocyte dysfunction, macrophage infiltration, and low-grade inflammation, which probably contributes to the induction of insulin resistance. Adipose tissue synthesizes and secretes numerous bioactive molecules, namely adipokines and cytokines, which affect the metabolism of both lipids and glucose. Disorders in the synthesis of adipokines and cytokines that occur in obesity lead to changes in lipid and carbohydrates metabolism and, as a consequence, may lead to insulin resistance and type 2 diabetes. Obesity is also associated with the accumulation of lipids. A special group of lipids that are able to regulate the activity of intracellular enzymes are biologically active lipids: long-chain acyl-CoAs, ceramides, and diacylglycerols. According to the latest data, the accumulation of these lipids in adipocytes
    [Show full text]
  • The Effects of Apelin on Hypothalamic–Pituitary–Adrenal Axis
    123 The effects of apelin on hypothalamic–pituitary–adrenal axis neuroendocrine function are mediated through corticotrophin- releasing factor- and vasopressin-dependent mechanisms Michael J F Newson, Emma M Roberts, George R Pope, Stephen J Lolait and Anne-Marie O’Carroll Henry Wellcome Laboratories for Integrative Neuroscience and Endocrinology, University of Bristol, Dorothy Hodgkin Building, Whitson Street, Bristol BS1 3NY, UK (Correspondence should be addressed to A-M O’Carroll; Email: [email protected]) Abstract The apelinergic system has a widespread expression in the (V1bR KO). Administration of pGlu-apelin-13 (1 mg/kg central nervous system (CNS) including the paraventricular i.c.v.) resulted in significant increases in plasma ACTH and nucleus, supraoptic nucleus and median eminence, and corticosterone (CORT), which were significantly reduced isolated cells of the anterior lobe of the pituitary. This pattern by pre-treatment with a-helical CRF9–41, indicating the of expression in hypothalamic nuclei known to contain involvement of a CRF-dependent mechanism. Additionally, corticotrophin-releasing factor (CRF) and vasopressin (AVP) pGlu-apelin-13-mediated increases in both plasma ACTH and to co-ordinate endocrine responses to stress has and CORT were significantly attenuated in V1bR KO generated interest in a role for apelin in the modulation of animals when compared with wild-type controls, indicating stress, perhaps via the regulation of hormone release from a role for the vasopressinergic system in the regulation of the pituitary. In this study, to determine whether apelin the effects of apelin on neuroendocrine function. Together, has a central role in the regulation of CRF and AVP these data confirm that the in vivo effects of apelin on neurones, we investigated the effect of i.c.v.
    [Show full text]
  • United States Patent (19) 11 Patent Number: 5,039,660 Leonard Et Al
    United States Patent (19) 11 Patent Number: 5,039,660 Leonard et al. (45. Date of Patent: Aug. 13, 1991 54 PARTIALLY FUSED PEPTIDE PELLET 4,667,014 5/1987 Nestor, Jr. et al. ................. 514/800 4,801,577 / 1989 Nestor, Jr. et al. ................. 54/800 75 Inventors: Robert J. Leonard, Lynnfield, Mass.; S. Mitchell Harman, Ellicott City, Primary Examiner-Lester L. Lee Md. Attorney, Agent, or Firm-Wolf, Greenfield & Sacks 73 Assignee: Endocon, Inc., South Walpole, Mass. (57) ABSTRACT 21 Appl. No.: 163,328 A bioerodible pellet capable of administering an even 22 Filed: Mar. 2, 1988 and continuous dose of a peptide over a period of up to a year, when subcutaneously implanted, is provided. (51) Int. Cl’.............................................. C07K 17/08 (52 U.S.C. .......................................... 514/8; 514/12; The bioerodible implant is a partially-fused pellet, 514/14: 514/15; 514/16; 514/17; 514/18; which pellet has a peptide drug homogeneously-bound 514/19; 514/800 in a matrix of a melted and recrystallized, nonpolymer Field of Search ................... 514/8, 12, 14, 15, 16, carrier. Preferably, the nonpolymer carrier is a steroid (58) and in particular is cholesterol or a cholesterol deriva 514/17, 18, 19, 800 tive. In one embodiment, the peptide drug is growth (56) References Cited hormone-releasing hormone. A method for making the U.S. PATENT DOCUMENTS bioerodible pellet also is provided. 4,164,560 8/1979 Folkman et al. .................... 424/427 '4,591,496 5/1986 Cohen et al. .......................... 424/78 13 Claims, 4 Drawing Sheets U.S. Patent Aug.
    [Show full text]
  • Apelin-13 Regulates Vasopressin-Induced Aquaporin-2 Expression and Trafficking in Kidney Collecting Duct Cells
    Cellular Physiology Cell Physiol Biochem 2019;53:687-700 DOI: 10.33594/00000016510.33594/000000165 © 2019 The Author(s).© 2019 Published The Author(s) by and Biochemistry Published online: online: 4 4October October 2019 2019 Cell Physiol BiochemPublished Press GmbH&Co. by Cell Physiol KG Biochem 687 Press GmbH&Co. KG, Duesseldorf BoulkerouaAccepted: 25 et September al.: Effect 2019 of Apelin-13 on Kidney Collectingwww.cellphysiolbiochem.com Duct Cells This article is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 Interna- tional License (CC BY-NC-ND). Usage and distribution for commercial purposes as well as any distribution of modified material requires written permission. Original Paper Apelin-13 Regulates Vasopressin-Induced Aquaporin-2 Expression and Trafficking in Kidney Collecting Duct Cells Chahrazed Boulkerouaa Houda Ayaria Taoufik Khalfaouia Mylène Lafrancea Élie Besserer-Offroya Nadia Ekindib Robert Sabbaghc,d Robert Dumainea,d Olivier Lesurd,e Philippe Sarreta,d Ahmed Chraibia,d aDepartment of Pharmacology & Physiology, Faculty of Medicine and Health Sciences, Sherbrooke University, Sherbrooke, QC, Canada, bDepartment of Pathology, Faculty of Medicine and Health Sciences, Sherbrooke University, Sherbrooke, QC, Canada, cDepartment of Surgery, Faculty of Medicine and Health Sciences, Sherbrooke University, Sherbrooke, QC, Canada, dResearch Center of the Centre Hospitalier Universitaire de Sherbrooke (CR-CHUS), Sherbrooke University, Sherbrooke, QC, Canada, eDepartment of Medicine, Faculty of Medicine and Health Sciences, Sherbrooke University, QC, Canada Key Words Kidney • Aquaporin • Apelin • Vasopressin • Confocal microscopy • PCR • mpkCCD Abstract Background/Aims: Apelin and its G protein-coupled receptor APJ (gene symbol Aplnr) are strongly expressed in magnocellular vasopressinergic neurons suggesting that the apelin/APJ system plays a key role at the central level in regulating salt and water balance by counteracting the antiduretic action of vasopressin (AVP).
    [Show full text]
  • A Potential Role of Apelin-13 Against Hepatic Injury and Metabolic Disorders in Preeclampsia Induced by L-NAME
    coatings Article A Potential Role of Apelin-13 against Hepatic Injury and Metabolic Disorders in Preeclampsia Induced by L-NAME Reham Z. Hamza 1,* , Abdel Aziz A. Diab 2, Mansour H. Zahra 2, Mai S. Attia 2, Suzan M. M. Moursi 3 and Najah M. Al-Baqami 4 1 Biology Department, Faculty of Sciences, Taif University, P.O. Box 11099, Taif 21944, Saudi Arabia 2 Zoology Department, Faculty of Science, Zagazig University, Zagazig 44519, Egypt 3 Medical Physiology Department, Faculty of medicine, Zagazig University, Zagazig 44519, Egypt 4 Department of Biological Sciences, Zoology, King Abdulaziz University, Jeddah 21589, Saudi Arabia * Correspondence: [email protected] or [email protected] or [email protected] Abstract: Background: Hypertensive disorders of pregnancy, gestational hypertension, and preeclamp- sia (PE) are exceptionally challenging, as their pathologies and therapeutic management simulta- neously influence the mother and embryo, sometimes putting their well-beings at odds with each other. Dysregulated lipid and glucose metabolism may be related to some cases of preeclampsia. Fluctuations in serum apelin levels may be attributed to changes in the serum levels of multiple interrelated factors such as insulin, insulin resistance, inflammatory cytokines, and nephritic dam- age. Previous studies demonstrated that apelin is an endogenous active peptide with vasodilatory and antioxidative-stress capabilities. Objective: We investigated the relationships among hepatic, nephrotic, and metabolic injuries in different preeclampsia-like mouse models and the potential effect Citation: Hamza, R.Z.; Diab, A.A.A.; of exogenous apelin administration on hepatic and nephrotic injuries and metabolic disorders in Zahra, M.H.; Attia, M.S.; Moursi, an N-nitro-L-arginine methyl ester (L-NAME) preeclampsia-like Sprague Dawley (SD) rat model.
    [Show full text]
  • Adipokines in the Skin and in Dermatological Diseases
    International Journal of Molecular Sciences Review Adipokines in the Skin and in Dermatological Diseases Dóra Kovács 1 , Fruzsina Fazekas 1, Attila Oláh 2 and Dániel Tör˝ocsik 1,* 1 Department of Dermatology, Faculty of Medicine, University of Debrecen, Nagyerdei krt. 98., 4032 Debrecen, Hungary; [email protected] (D.K.); [email protected] (F.F.) 2 Department of Physiology, Faculty of Medicine, University of Debrecen, Nagyerdei krt. 98., 4032 Debrecen, Hungary; [email protected] * Correspondence: [email protected]; Tel.: +36-52-255-602 Received: 31 October 2020; Accepted: 25 November 2020; Published: 28 November 2020 Abstract: Adipokines are the primary mediators of adipose tissue-induced and regulated systemic inflammatory diseases; however, recent findings revealed that serum levels of various adipokines correlate also with the onset and the severity of dermatological diseases. Importantly, further data confirmed that the skin serves not only as a target for adipokine signaling, but may serve as a source too. In this review, we aim to provide a complex overview on how adipokines may integrate into the (patho) physiological conditions of the skin by introducing the cell types, such as keratinocytes, fibroblasts, and sebocytes, which are known to produce adipokines as well as the signals that target them. Moreover, we discuss data from in vivo and in vitro murine and human studies as well as genetic data on how adipokines may contribute to various aspects of the homeostasis of the skin, e.g., melanogenesis, hair growth, or wound healing, just as to the pathogenesis of dermatological diseases such as psoriasis, atopic dermatitis, acne, rosacea, and melanoma.
    [Show full text]
  • Apelin‑13 Attenuates ER Stress‑Associated Apoptosis Induced by MPP+ in SH‑SY5Y Cells
    1732 INTERNATIONAL JOURNAL OF MOleCular meDICine 42: 1732-1740, 2018 Apelin‑13 attenuates ER stress‑associated apoptosis induced by MPP+ in SH‑SY5Y cells YUNLU JIANG1, HAIQING LIU2, BINGYUAN JI1, ZHENGWEN WANG1, CHUNMEI WANG1, CHUNQING YANG1, YANYOU PAN1, JING CHEN3, BAOHUA CHENG1 and BO BAI1 1Neurobiology Institute, Jining Medical University, Jining, Shandong 272067; 2Department of Physiology, Taishan Medical College, Taian, Shandong 271000, P.R. China; 3Division of Biomedical Sciences, Warwick Medical School, University of Warwick, Coventry CV4 7AL, UK Received October 12, 2017; Accepted May 31, 2018 DOI: 10.3892/ijmm.2018.3719 Abstract. Apelin-13, a neuropeptide that acts as a ligand for GRP78, CHOP and cleaved caspase-12 in MPP+-treated a putative receptor related to the angiotensin II type receptor, SH‑SY5Y cells, and significantly enhanced the expression elicits neuroprotective effects in numerous neurological condi- levels of phospho-ERK1/2. Taken together, the present results tions, such as Huntington's disease and cerebral ischemia. support a model in which apelin-13 inhibits MPP+-induced Parkinson's disease (PD), one of the most prevalent neuro- apoptosis of SH-SY5Y cells by decreasing the expression of degenerative diseases, is caused by damage to neurons in the GRP78, CHOP, and cleaved caspase-12, and by increasing the brain; however, the underlying mechanism remains unclear. expression of phospho-ERK1/2. The present findings suggest The present study explored the effects of apelin-13 on SH-SY5Y that apelin-13 may be useful for the treatment of PD. human neuroblastoma cells treated with 1-methyl-4-phenyl- pyridine (MPP+). Cell growth, cell viability, and apoptosis Introduction were measured by real-time cell analysis, the Cell Counting Kit-8 assay, and flow cytometry, respectively.
    [Show full text]